The first phase III clinical study of PARP inhibitor for adjuvant treatment of early breast cancer, OlympiA study, aims to evaluate the efficacy and safety of olaparib compared with placebo in the adjuvant treatment of early breast cancer with clinically and pathologically high-risk, HER2-negative, BRCA1/2 mutation. This evidence concerns the gene BRCA1 and breast cancer.